亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

医学 重症肌无力 耐受性 不利影响 抗原 嵌合抗原受体 自身抗体 免疫疗法 内科学 胃肠病学 免疫学 抗体 癌症
作者
Volkan Granit,Michael Benatar,Metin Kurtoğlu,Miloš D. Miljković,Nizar Chahin,Gregory Sahagian,Marc H. Feinberg,Adam Slansky,Tuan Vu,Christopher M. Jewell,Michael S. Singer,Murat V. Kalayoglu,James F. Howard,Tahseen Mozaffar,Volkan Granit,Michael Benatar,Tahseen Mozaffar,Nizar Chahin,James F. Howard,Adam D. Slansky,Marc H. Feinberg,Gregory Sahagian,Tuan Vu,Denise Pereira,Julie Steele,Maria Elena Paredes,Cara L. Benjamin,Krishna V. Komanduri,Ali A. Habib,Julia Kimberly Fong,Luis de la Cruz‐Merino,Diana Dimitrova,Manisha Chopra,Keith E. Holley,Gabrielle DeMaria,April Tenorio,Naraly Requena,Beverly Mackanzie Brooks,Niraja Suresh,Jerrica Farias,Miloš D. Miljković,Metin Kurtoğlu,M. Casi,Adam Chowdhury,Hafsa Kamboh,Charles A. Stewart,Mehmet Tosun,Yufei Shan,S. E. Daniel,Matthew T. Duvernay,Maria L. Kireeva,Emily English,Christopher M. Jewell,Michael S. Singer,Murat V. Kalayoglu
出处
期刊:Lancet Neurology [Elsevier]
卷期号:22 (7): 578-590 被引量:65
标识
DOI:10.1016/s1474-4422(23)00194-1
摘要

Background Chimeric antigen receptor (CAR) T cells are highly effective in treating haematological malignancies, but associated toxicities and the need for lymphodepletion limit their use in people with autoimmune disease. To explore the use of CAR T cells for the treatment of people with autoimmune disease, and to improve their safety, we engineered them with RNA (rCAR-T)—rather than the conventional DNA approach—to target B-cell maturation antigen (BCMA) expressed on plasma cells. To test the suitability of our approach, we used rCAR-T to treat individuals with myasthenia gravis, a prototypical autoantibody disease mediated partly by pathogenic plasma cells. Methods MG-001 was a prospective, multicentre, open-label, phase 1b/2a study of Descartes-08, an autologous anti-BCMA rCAR-T therapy, in adults (ie, aged ≥18 years) with generalised myasthenia gravis and a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or higher. The study was done at eight sites (ie, academic medical centres or community neurology clinics) in the USA. Lymphodepletion chemotherapy was not used. In part 1 (phase 1b), participants with Myasthenia Gravis Foundation of America (MGFA) disease class III–IV generalised myasthenia gravis received three ascending doses of Descartes-08 to determine a maximum tolerated dose. In part 2 (phase 2a), participants with generalised myasthenia gravis with MGFA disease class II–IV received six doses at the maximum tolerated dose in an outpatient setting. The primary objective was to establish safety and tolerability of Descartes-08; secondary objectives were to assess myasthenia gravis disease severity and biomarkers in participants who received Descartes-08. This trial is registered with clinicaltrials.gov, NCT04146051. Findings We recruited 16 individuals for screening between Jan 7, 2020 and Aug 3, 2022. 14 participants were enrolled (n=3 in part 1, n=11 in part 2). Ten participants were women and four were men. Two individuals did not qualify due to low baseline MG-ADL score (n=1) or lack of generalised disease (n=1). Median follow-up in part 2 was 5 months (range 3–9 months). There was no dose-limiting toxicity, cytokine release syndrome, or neurotoxicity. Common adverse events were headache (six of 14 participants), nausea (five of 14), vomiting (three of 14), and fever (four of 14), which resolved within 24 h of infusion. Fevers were not associated with increased markers of cytokine release syndrome (IL-6, IL-2, and TNF). Mean improvements from baseline to week 12 were –6 (95% CI –9 to –3) for MG-ADL score, –7 (–11 to –3) for Quantitative Myasthenia Gravis score, –14 (–19 to –9) for Myasthenia Gravis Composite score, and –9 (–15 to –3) for Myasthenia Gravis Quality of Life 15-revised score. Interpretation In this first study of an rCAR-T therapy in individuals with an autoimmune disease, Descartes-08 appeared to be safe and was well tolerated. Descartes-08 infusions were followed by clinically meaningful decreases on myasthenia gravis severity scales at up to 9 months of follow-up. rCAR-T therapy warrants further investigation as a potential new treatment approach for individuals with myasthenia gravis and other autoimmune diseases. Funding Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lalala大鸭梨完成签到,获得积分10
18秒前
阿杰完成签到 ,获得积分10
30秒前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
隐形曼青应助健忘绿茶采纳,获得10
2分钟前
2分钟前
哲别发布了新的文献求助10
2分钟前
白熊IceBear完成签到,获得积分10
3分钟前
jyy应助想毕业的橙子采纳,获得10
3分钟前
CodeCraft应助科研通管家采纳,获得10
3分钟前
4分钟前
4分钟前
5分钟前
健忘绿茶发布了新的文献求助10
5分钟前
英姑应助科研通管家采纳,获得10
5分钟前
赘婿应助对流域采纳,获得10
5分钟前
5分钟前
对流域发布了新的文献求助10
5分钟前
6分钟前
裴敏发布了新的文献求助10
6分钟前
6分钟前
梵星完成签到 ,获得积分10
6分钟前
6分钟前
健忘绿茶完成签到,获得积分10
7分钟前
机灵自中发布了新的文献求助10
7分钟前
呃呃诶发布了新的文献求助20
7分钟前
科研通AI2S应助科研通管家采纳,获得10
7分钟前
可爱的函函应助机灵自中采纳,获得10
7分钟前
科研通AI2S应助Mia采纳,获得10
7分钟前
科研通AI2S应助SDNUDRUG采纳,获得10
8分钟前
小王完成签到 ,获得积分10
8分钟前
充电宝应助泡面小猪采纳,获得10
8分钟前
9分钟前
lcs完成签到,获得积分10
9分钟前
xiuxiuzhang完成签到 ,获得积分10
9分钟前
CodeCraft应助科研通管家采纳,获得10
9分钟前
9分钟前
呃呃诶完成签到,获得积分10
9分钟前
9分钟前
FashionBoy应助秋刀鱼不过期采纳,获得10
9分钟前
9分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137011
求助须知:如何正确求助?哪些是违规求助? 2787960
关于积分的说明 7784139
捐赠科研通 2444060
什么是DOI,文献DOI怎么找? 1299685
科研通“疑难数据库(出版商)”最低求助积分说明 625497
版权声明 600997